H

Hualan Biological Bacterin Inc
SZSE:301207

Watchlist Manager
Hualan Biological Bacterin Inc
SZSE:301207
Watchlist
Price: 18.08 CNY -2.01% Market Closed
Market Cap: 10.9B CNY
Have any thoughts about
Hualan Biological Bacterin Inc?
Write Note

Hualan Biological Bacterin Inc
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hualan Biological Bacterin Inc
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
H
Hualan Biological Bacterin Inc
SZSE:301207
Total Current Assets
ÂĄ5.2B
CAGR 3-Years
28%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Current Assets
ÂĄ29.8B
CAGR 3-Years
-3%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Current Assets
ÂĄ11B
CAGR 3-Years
-6%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Current Assets
ÂĄ10.3B
CAGR 3-Years
73%
CAGR 5-Years
64%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Current Assets
ÂĄ46.8B
CAGR 3-Years
29%
CAGR 5-Years
41%
CAGR 10-Years
40%
Imeik Technology Development Co Ltd
SZSE:300896
Total Current Assets
ÂĄ4.3B
CAGR 3-Years
-1%
CAGR 5-Years
70%
CAGR 10-Years
N/A
No Stocks Found

Hualan Biological Bacterin Inc
Glance View

Market Cap
10.8B CNY
Industry
Biotechnology

In the bustling landscape of biotechnology, Hualan Biological Bacterin Inc. emerges as a formidable player. This Chinese company, rooted in the province of Henan, has carved its niche in the development and manufacture of human vaccines. Hualan's journey began with a focused vision on advancing public health through immunization. Today, it stands among the largest producers of human vaccines in China, adeptly navigating the stringent regulatory environments that govern this critical sector. The company's innovative approach in vaccine research is bolstered by state-of-the-art facilities and an unwavering commitment to quality, enabling it to produce safe, effective, and affordable vaccines. Over the years, Hualan has expanded its portfolio to include vaccines for influenza, rabies, and measles, to name a few, each product carefully developed to meet domestic and international health needs. Hualan Biological Bacterin Inc. generates its revenues substantially through the sale of these vaccines. The company's business model leans heavily on its strong distribution network, which ensures that its products effectively reach healthcare providers and institutions across China. Regulatory approvals for new vaccines further pave the way for market expansion and potential export opportunities, contributing to revenue growth. Furthermore, the company strategically invests in research and development, consistently working on new immunological breakthroughs, thus securing its standing and paving the way for future revenue streams. Through this meticulous combination of development, regulatory savvy, and strategic distribution, Hualan not only sustains its financial health but continues to play a vital role in advancing global public health.

Intrinsic Value
30.95 CNY
Undervaluation 42%
Intrinsic Value
Price
H

See Also

What is Hualan Biological Bacterin Inc's Total Current Assets?
Total Current Assets
5.2B CNY

Based on the financial report for Dec 31, 2023, Hualan Biological Bacterin Inc's Total Current Assets amounts to 5.2B CNY.

What is Hualan Biological Bacterin Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
40%

Over the last year, the Total Current Assets growth was 25%. The average annual Total Current Assets growth rates for Hualan Biological Bacterin Inc have been 28% over the past three years , 40% over the past five years .

Back to Top